ESR1 and breast carcinoma: Our study also found that AMP-induced growth suppression of breast cancer cells is independent of estrogen receptor status, supported by observations that pretreatment with ICI182780, an anti-estrogen, did not alter the sensitivity of estrogen receptor-positive MCF-7 to AMP treatment.